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Liver fibrosis and Gd-EOB-DTPA-
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correlation
Niklas Verloh1, Kirsten Utpatel2, Michael Haimerl1, Florian Zeman3, Claudia Fellner1, 
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Gadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid (Gd-EOB-DTPA) is a hepatocyte-specific 
MRI contrast agent. Because the hepatic uptake of Gd-EOB-DTPA depends on the integrity of the 
hepatocyte mass, this uptake can be quantified to assess liver function. We report the relationship 
between the extent of Gd-EOB-DTPA uptake and the degree of liver fibrosis. T1-weighted volume-
interpolated breath-hold examination (VIBE) sequences with fat suppression were acquired before 
and 20 minutes after contrast injection. Strong correlations of the uptake characteristics of Gd-
EOB-DTPA with the relative enhancement (RE) of the liver parenchyma and the grade of fibrosis/
cirrhosis, classified using the Ishak scoring system, were observed. The subdivisions between the 
grades of liver fibrosis based on RE were highly significant for all combinations, and a ROC revealed 
sensitivities ≥82% and specificities ≥87% for all combinations. MR imaging is a satisfactorily 
sensitive method for the assessment of liver fibrosis/cirrhosis.
MR imaging of the liver using the liver-specific contrast agent Gd-EOB-DTPA has gained attention 
in recent years. Gd-EOB-DTPA is an ionic complex consisting of gadolinium (III) and the ligand 
ethoxybenzyl-diethylenetriaminepentaacetic acid (EOB-DTPA). These biochemical properties allow 
for the general assessment of tissue perfusion in vascular phases in addition to the specific accumula-
tion in hepatocytes in the late phase (hepatobiliary phase, HBP) after 20 minutes1–4. The ethoxybenzyl 
group promotes the transport of Gd-EOB-DTPA into hepatocytes through the organ-anion transporters 
(OATPB1/B3) found in the sinusoids5–8. Gadolinium uptake shortens the spin-lattice relaxation time in 
the corresponding tissue, which leads to an increase in signal intensity (SI) on T1-weighted images1–3,9. 
Gd-EOB-DTPA is excreted through the ATP-dependent multidrug resistance protein 2 (MRP2), which is 
located in the canalicular membrane10,11. The excretion of Gd-EOB-DTPA into the biliary ducts is limited 
and causes a temporary enhancement within the liver cells12.
Due to the liver-specific accumulation of Gd-EOB-DTPA in the HBP, which leads to increased SI 
in the liver parenchyma, this molecule is particularly suitable for the detection and characterization 
of liver lesions13–15. However, based on various clinical and biochemical parameters, the uptake of 
Gd-EOB-DTPA depends on liver function16–22. The underlying liver pathology that causes the delayed 
uptake of Gd-EOB-DTPA has not been thoroughly examined. The aim of this study was to determine 
the correlation of the extent of Gd-EOB-DTPA with the degree of liver fibrosis (LF).
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Results
Patients. No significant differences in the patients’ ages, genders, body weights, heights or BMIs were 
identified between the patients with normal liver function and those with liver disease. Table 1 provides 
a summary of the patient characteristics.
Differences in MR imaging between the patients with and without liver fibrosis. The mean 
SI between the non-contrast phase (179.39 ± 32.82) and the Gd-EOB-DTPA-enhanced phase 
(307.80 ± 88.10) exhibited a significant increase in all patients (p ≤ 0.001). The average relative enhance-
ment (RE) was 0.71 ± 0.33.
In the non-contrast sequences, the SI differed significantly (p = 0.018) between the patients with normal 
liver parenchyma (no liver fibrosis (NLF); 199.15 ± 39.09) and those in any stage of LF (175.24 ± 23.00). 
Following the application of Gd-EOB-DTPA, this difference increased (p ≤ 0.001) (NLF, 421.10 ± 71.21 
and LF, 284.02 ± 71.39). The RE was significantly different (p ≤ 0.001) between the patients with NLF 
(1.13 ± 0.18) and those with LF (0.62 ± 0.29).
Comparison of different sample acquisition methods. A significant difference (p = 0.031) 
between the patients who underwent liver resection and those who underwent needle biopsy was 
observed in terms of RE. The patients who underwent needle biopsy exhibited a significantly lower RE 
(0.62 ± 0.38) than the patients who underwent liver resection (0.76 ± 0.30). No significant differences 
were observed regarding SI (Table 2).
Comparison of the different stages of liver fibrosis. A comparison between the patients with NLF 
and those with LF as stratified according to the Ishak classification revealed that SI generally decreased 
in the cases of fibrosis (Tables  3–4, Fig.  1). Significant differences were observed in the RE between 
the patients without fibrosis (NLF, Ishak = 0; RE, 1.13 ± 0.18) and those with mild liver fibrosis (MLF, 
Ishak = 1; RE, 0.89 ± 0.14) (p ≤ 0.001) and between the patients with MLF and those with advanced liver 
fibrosis (ALF, Ishak 2 + 3; RE, 0.77 ± 0.16; p = 0.005). However, no significant differences were observed 
between the patients with Ishak 2 and 3 fibrotic scores (p = 0.255). The patients with severe liver fibrosis 
(SLF, Ishak 4 + 5) exhibited significantly (p ≤ 0.001) lower RE (0.46 ± 0.20) than the patients with ALF; 
however, no significant differences (p = 0.054) were observed between the patients with Ishak scores of 
4 and 5. Comparison of the patients with SLF and those with liver cirrhosis (LC, Ishak = 6) revealed a 
significant difference (p = 0.002) in RE. Figure 2 shows the boxplots and the corresponding significance 
values for the patients with NLF and those with different stages of LF.
ROC analysis. We performed receiver operating characteristic (ROC) analysis to differentiate NLF 
from LF and the different stages of fibrosis based on the RE of the HBP.
Figure 3 shows the ROC curves according to four different fibrosis stage thresholds: MLF or greater 
(Ishak ≥ 1), ALF or greater (Ishak ≥ 2), SLF or greater (Ishak ≥ 4), and LC (Ishak = 6). The optimal 
All (n = 98) NLF (n = 17) LF (n = 81) p-value
Age (years) 57.49 ± 14.25 56.35 ± 16.85 57.73 ± 13.75 p = 0.888
Gender p = 0.66
 Men, n (%) 65 (66) 8 (47) 57 (70)
 Women, n (%) 33 (34) 9 (53) 24 (30)
Height (m) 1.72 ± 0.09 1.72 ± 0.10 1.72 ± 0.09 p = 0.829
Weight (kg) 80.59 ± 16.43 78.59 ± 18.18 81.01 ± 16.13 p = 0.567
BMI 27.03 ± 4.65 26.29 ± 4.99 27.19 ± 4.59 p = 0.302
Table 1.  Patient characteristics. The values indicate the mean ± the standard deviation unless otherwise 
indicated. NLF, no liver fibrosis LF, liver fibrosis BMI, body mass index.
Needle biopsy Liver resection p-value
Mean SI non-contrast 181.77 ± 34.82 177.88 ± 31.70 0.771
Mean SI HBP 295.27 ± 90.16 315.73 ± 86.59 0.196
RE 0.62 ± 0.38 0.76 ± 0.30 0.031
Table 2.  Signal intensities and relative enhancements of the liver parenchyma for patients undergoing 
needle biopsy or liver resection. The values indicate the mean ± the standard deviation. SI, signal intensity 
RE, relative enhancement HBP, hepatobiliary phase.
www.nature.com/scientificreports/






Figure 1. Images comparing the plain and hepatobiliary phases T1-weighted VIBE sequence with fat 
suppression for the non-contrast (1st column) and hepatobiliary phase (2nd column) of a patient with 
normal liver parenchyma (A) and for patients with different stages of liver fibrosis (B–E) with the 
corresponding histopathology images with the EVG staining (3rd column). All images displayed were 
taken with the same window and center level. The scale on the histopathology images represents 500 μ m. The 
relative enhancements of the liver parenchyma between the plain and Gd-EOB-DTPA-enhanced images were 
as follows: (A) no liver fibrosis (Ishak 0), RE: 1.01 (B) mild liver fibrosis (Ishak 1), RE: 0.84 (C) advanced liver 
fibrosis (Ishak 2), RE: 0.65 (D) severe liver fibrosis (Ishak 4), RE: 0.34 (E) liver cirrhosis (Ishak 6), RE: 0.16.
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Figure 2. Relative enhancements during the hepatobiliary phase in patients with normal liver 
parenchyma and patients with liver fibrosis. Mann-Whitney U-tests were used to compare the following 
groups: RE, relative enhancement NLF, no liver fibrosis MLF, mild liver fibrosis ALF, advanced liver fibrosis 
SLF, severe liver fibrosis LC, liver cirrhosis.
Figure 3. ROC analysis Graphs illustrating the ROC curves for the relative enhancement measurements 
for the diagnoses of the patients in (A) (Ishak ≥ 1; cut-off, 0.90), (B) (Ishak ≥ 2; cut-off, 0.79), (C) 
(Ishak ≥ 4; cut-off, 0.60) and (D) (Ishak = 6; cut-off, 0.47). 
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5Scientific RepoRts | 5:15408 | DOi: 10.1038/srep15408
cut-off values, the corresponding sensitivities and specificities values and the areas under the curves are 
presented in Table 5.
The optimal cut-off value for the RE to differentiate NLF from LF was 0.90 (area under the curve (AUC) 
0.94). This cut-off value resulted in a sensitivity of 82% and a specificity of 100% for this differentiation.
Discussion
Hepatic fibrosis and cirrhosis are currently considered dynamic processes. Following adequate treatment 
of the underlying disease, LF can regress to a re-compensation phase23. Tests can detect the early signs 
of impaired liver function and lead to readjustments in patient treatment and subsequent slowing in the 
dynamic process of fibrosis. Obtaining a liver biopsy is the gold standard in the diagnosis and assessment 
of LF and LC in clinical practice. Liver biopsies are invasive procedures. They have poor patient compli-
ance; are prone to sampling errors; are subject to inter-observer variability; and are associated with risks 
of complications, such as infection and bleeding24. The lack of characteristic fibrotic septa and nodular 
configurations can further complicate the histological diagnosis of LF or LC25. Furthermore, faulty sam-
pling can underestimate the severity of the disease26,27.
In liver imaging, an upper abdominal ultrasonography should also be considered as a diagnostic tool 
for the assessment of liver function. Using elastography, liver stiffness can be measured, and indirect 
results regarding the degree of fibrosis can thus be obtained28,29. However, dynamic investigations are 
limited in their diagnostic capabilities due to their characteristics and false readings that result from 
incorrect measurements. Limited reproducibility and examiner dependence are also important limiting 
factors30.
In addition to ultrasound imaging, MR imaging of the liver with hepatocyte-specific MR contrast 
agents is currently an important method of investigation. Gd-EOB-DTPA is a hepatocyte-specific MR 
contrast agent that exhibits OATP1-mediated uptake and MRP2-mediated biliary excretion31. Because 
the hepatic uptake of Gd-EOB-DTPA is dependent on the integrity of the hepatocyte mass, quantifica-
tion of the uptake via mean values of RE can be used to assess liver function16,19,21,32,33. The uptake of the 
contrast agent exhibits a significant correlation with the clinical degree of cirrhosis22,34.
Only a few studies have compared liver function as assessed by parenchyma enhancement fol-
lowing Gd-EOB-DTPA administration with histopathologic data. Variable diagnostic performance of 
All No fibrosis Fibrosis
Mean SI non-contrast 179.39 ± 32.82 199.15 ± 39.09 175.24 ± 23.00
Mean SI HBP 307.80 ± 88.10 421.10 ± 71.21 284.02 ± 71.39
RE 0.71 ± 0.33 1.13 ± 0.18 0.62 ± 0.29
Table 3.  Signal intensities and relative enhancements of the liver parenchyma for the patients with and 
without fibrosis. The values indicate the mean ± the standard deviation. SI, signal intensity RE, relative 
enhancement HBP, hepatobiliary phase.
Appearance N Mean SI non-contrast Mean SI HBP RE Ishak
No fibrosis 17 199.15 ± 39.09 421.10 ± 71.21 1.13 ± 0.18 0 NLF
Fibrosis expansion in some 
portal areas± short fibrous septa 20 177.58 ± 25.99 336.57 ± 57.30 0.89 ± 0.14 1 MLF
Fibrosis expansion in most 
portal areas± short fibrosis septa 19 176.04 ± 25.94 313.09 ± 42.39 0.79 ± 0.17 2
ALFFibrosis expansion in most 
portal areas with occasional 
portal to portal (P-P) bridging
5 170.45 ± 40.69 292.59 ± 68.35 0.70 ± 0.10 3
Fibrosis expansion in portal 
areas with marked P-P bridging 
and P-C bridging
8 169.13 ± 24.15 266.23 ± 53.24 0.57 ± 0.21 4
SLF
Marked bridging (P-P and/or 
P-C) with occasional nodules 
(incomplete cirrhosis)
9 184.96 ± 34.67 257.34 ± 79.20 0.37 ± 0.14 5
Cirrhosis, probable or definite 20 171.39 ± 38.31 220.82 ± 62.65 0.28 ± 0.11 6 LC
Table 4.  Signal intensities and relative enhancements of the liver parenchyma of the patients classified 
according to the degree of specific fibrosis/cirrhosis. The values indicate the mean ± the standard 
deviation. SI, signal intensity RE, relative enhancement HBP, hepatobiliary phase NLF, no liver fibrosis MLF, 
mild liver fibrosis ALF, advanced liver fibrosis SLF, severe liver fibrosis LC, liver cirrhosis.
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Gd-EOB-DTPA-enhanced MR imaging with AUCs ranging from 0.63 and 0.85 has been reported. These 
studies have used RE35, the liver-to-spleen ratio20 or dynamic measurements36 to quantify the parenchy-
mal enhancement. Feier et al. reported a good correlation between the hepatic uptake of Gd-EOB-DTPA 
as expressed by RE and the METAVIR scoring system; however, these authors were unable to differentiate 
the patients with NLF from the patients with initial fibrosis in a pairwise comparison35. Feier et al. relied 
only on liver biopsies for the classification of LF. As mentioned above, liver biopsies may suffer from 
sampling errors and could have led to overlap between the groups.
Our results revealed a significant difference (p = 0.018) in the SIs of the patients with NLF and those 
with any stage of LF on the non-contrast T1-weighted images. This change in SI might have been caused 
by a change in liver architecture in the patients with LF. However, the evidence regarding surrounding 
this question has been contradictory. Ito et al. and Bataller et al. reported increases in the accumula-
tions of iron, copper, manganese and collagen in cases of LC37,38. These paramagnetic macromolecules 
induce T1-shortening effects that would result in increased T1-weighted SIs on non-contrast images. 
However, Lee et al. reported that the liver parenchyma is often edematous in cases of early stage fibrosis 
due to new vessels that have leaky interendothelial junctions and result in increased portions of pro-
teins and red blood cells in the extravascular space39. This process results in the increased deposition 
of hepatic water content, hypercellularity and an increased ratio of free bound water in the liver paren-
chyma. Consequently, this process results in a prolonged T1 relaxation time40,41 that leads to reduced 
SI on non-contrast T1-weighted images and vice versa. Accounting for these controversial findings, 
non-enhanced MRI is unlikely to be an appropriate method for the detection and staging of LF.
In accordance with previous findings, a significant association of the degree of fibrosis and the signal 
enhancement due to Gd-EOB-DTPA in the late phase after 20 min was detected in the present study 
population. A corresponding drop in SI was observed with an increase in fibrosis. However, the different 
Ishak stages could not be fully recapitulated.
Comparison of the patients with NLF and those with initial fibrotic remodeling (Ishak 1, MLF) 
revealed a significant (p ≤ 0.001) drop in RE. In accordance with the morphologic data that described 
an increase in fibrotic tissue that was more dominant at higher stages42, we observed that the decrease 
in RE was lower from mild (Ishak 1) to advanced (Ishak 2 + 3) LF compared with advanced to severe 
LF (Ishak 4 + 5).
The distinction between normal parenchyma and fibrotic remodeling is particularly useful for initial 
patient monitoring or screening because this difference could result in the initiation of therapy in the 
early stages of fibrosis, which would lead to early interventions and slowing of the progression. Under 
conditions of adequate therapy, the fibrotic remodeling process is reversible23.
Therapy monitoring using MR imaging offers the advantage of a non-invasive method for treating the 
progression of LF/LC. As a diagnostic modality, MR imaging eliminates the risks of liver biopsy (i.e., infec-
tion, bleeding, and sampling errors) and can provide information regarding hepatic fibrosis and cirrhosis.
The limiting factor of this study is the fact that both the histological data from the liver biopsies and 
those of the samples of the liver resections were used. A significant difference between the two patient 
groups was observed in terms of RE. This difference might have occurred because the patients who 
underwent needle biopsies were more likely to be at an advanced stage of LF/LC (mean ISHAK 3.3) 
because the needle biopsies were performed as active patient monitoring in cases of known LC com-
pared with the patients who underwent liver resection (mean ISHAK 2.5). Additionally, this difference in 
material quality might have led to variations in the histological diagnoses, particularly variations related 
to the differentiations of the fibrotic expansions between the patients with Ishak scores of 2 and 3 and 
the distinction between patients with ALF (Ishak 4) and patients with incomplete cirrhosis (Ishak 5). 
However, only liver biopsies were used, and the punch-cylinders were always longer than 15 mm, and at 
least 10 cut portal fields were utilized; thus, tissue volumes sufficient for analysis were obtained.
Regarding the aim and original purpose of this study, the following assumption was confirmed: the 
uptake of Gd-EOB-DTPA depends on the severity of fibrosis and the degree of cirrhosis. We showed that 
the patients with hepatic impairments exhibited reduced signal amplifications in the HBP. Consequently, 
the uptake of Gd-EOB-DTPA was used to obtain information regarding liver function.
In conclusion, we strongly believe that in terms of risk-benefit analyses, MRI is a good and sensitive 
method for determining the degree of LF/LC.
Ishak ≥ 1 Ishak ≥ 2 Ishak ≥ 4 Ishak = 6
RE cut-off 0.90 0.79 0.60 0.47
Sensitivity (%) 82 87 95 100
Specificity (%) 100 87 95 90
AUC (95% CI) 0.94 (0.90, 1.00) 0.93 (0.87, 0.98) 0.98 (0.94, 1.00) 0.96 (0.92, 0.99)
Table 5.  Optimal cut-off values and the corresponding sensitivity and specificity values for the 
differentiation of the different fibrosis stage thresholds. RE, relative enhancement.
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Materials and Methods
Patients. Approval from the local institutional review board of the University Hospital Regensburg 
was obtained, and this retrospective study was performed in accordance with the relevant guidelines 
and regulations. Written informed consent for the use of the tissue samples and MR images for scientific 
research was obtained from study participant.
One hundred ninety-three consecutive patients were recruited from 02/2012 to 10/2014. Patients who 
had undergone Gd-EOB-DTPA-enhanced MR imaging of the liver and provided histopathological liver 
samples within three months of the examination were included in our study.
The adult patients had undergone Gd-EOB-DTPA-enhanced MR imaging and histopathological 
examinations of the liver due to the presence of suspected focal hepatic lesions or for the monitoring of 
active hepatocellular carcinomas in cases of known LC. None of the recruited patients had any contrain-
dications for MRI examination (e.g., claustrophobia, incompatible metallic implants, and pacemakers), 
contraindications for the administration of Gd-EOB-DTPA (e.g., renal failure as defined by a glomerular 
filtration rate below 30 ml/min) or histories of previous reactions to liver-specific MRI contrast agents.
Seventy-four patients were excluded from this study due to insufficient liver samples (n = 56; tissue 
lengths shorter than 15 mm and/or less than ten visible portal tracts) or sampling errors (n = 18), and 
an additional 21 patients were excluded due to the inability to complete the full MR imaging protocol 
and the presence of severe imaging artifacts due to surgical clips or poor breath-holding techniques.
Ultimately, 98 patients (65 men and 33 women; mean age, 57.5 ± 14.3 years) were included in our 
study.
MR imaging. All imaging was performed using a clinical whole-body 3-T system (Magnetom Skyra, 
Siemens Healthcare) and combination body-spine array coil elements (18-channel body matrix coil 
and 32-channel spine matrix coil) for signal reception. Each of the T1-weighted volume-interpolated 
breath-hold examination (VIBE) sequences with fat suppression (repetition time (TR), 3.09 ms; 
echo time (TE), 1.16 ms; flip angle, 9°; parallel imaging factor, 2; slices, 64; reconstructed voxel size, 
1.3 × 1.3 × 3.0 mm; measured voxel size, 1.7 × 1.3 × 4.5 mm; acquisition time, 14 s) covered the entire 
liver, and the sequences were applied before (non-contrast) and 20 min after contrast injection (HBP). 
Each sequence was acquired during one breath-hold, and no additional system adjustments were per-
formed for the post-contrast sequence.
All patients received a Gd-EOB-DTPA (Primovist, Eovist; Bayer Schering Pharma AG, Berlin, 
Germany) dose that was adapted for their respective body weights (0.025 mmol/kg body weight). The 
hepatocytic contrast agent Gd-EOB-DTPA was administered via bolus injection with a flow rate of 1 ml/s 
and flushed with 20 ml NaCl.
Image analysis. To determine the mean SI, three regions of interest (ROIs) were manually placed in 
each liver lobe (with identical sizes and locations for every sequence) and excluded visible vessels, liver 
lesions and imaging artifacts at the workstation of the MR scanner (Fig.  4). The ROIs were manually 
adjusted between sequences in cases of patient movement. The sizes of the ROIs ranged from 1.0 to 
3.5 cm2, and the largest possible regions were chosen. The mean SI of these ROIs was taken as the rep-
resentative SI for the entire liver.
The RE between the pre- and post-Gd-EOB-DTPA enhancements was calculated as follows:
Figure 4. ROI placement This figure displays the region of interest (ROI) placements in the  
non-contrasted images and during the hepatobiliary phase for a patient with no liver fibrosis. 
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SIpre is the mean SI of the liver parenchyma before (non-contrast), and SIpost is the mean SI of the liver 
parenchyma 20 minutes after Gd-EOB-DTPA administration (HBP). The RE was used to determine the 
Gd-EOB-DTPA uptake into the liver parenchyma and was then correlated with the histopathological findings.
Histopathological examination. In the present study, both liver biopsies (n = 38) and partial liver 
resections (n = 60) were included. The liver biopsies were collected as a part of active patient monitoring 
in cases of known LC (n = 21) or unknown liver tumors (n = 17). Patients underwent liver resection due 
to liver transplantation (n = 4) or as treatment method in cases of metastasis (n = 27) and liver cancer 
(HCC, n = 23; CCC, n = 6).
All samples were fixed in formalin and embedded in paraffin. Four-micrometer sections were cut ver-
tically and mounted on glass slides. Thereafter, the sections were deparaffinized with xylene and ethanol 
and stained with hematoxylin-eosin (HE) and Elastica van Gieson (EVG) according to standard proto-
cols. EVG staining was used to evaluate LF. Collagen stained red, and the hepatocytes stained yellow.
For the liver biopsies, an automatic needle device was used to obtain the liver samples. The length of 
each biopsy specimen was measured, and the numbers of portal spaces were assessed. The liver samples 
were included in the evaluations only when the tissue length exceeded 15 mm and more than ten portal 
tracts were visible. Only non-tumorous liver biopsies were included in this study. Two pathologists (M.E. 
and K.U.) who specialize in liver histopathology reviewed the biopsies or resection specimens to evaluate 
the degrees of specific fibrosis/cirrhosis. Both readers were blinded to the imaging results and the patient 
data. The scoring was performed independently. In cases of disagreements in terms of a common final 
judgment, additional microscopic analyses were performed together. The fibroses were graded using the 
Ishak scoring system43. The patients were subdivided into the following 5 categories: NLF (Ishak 0; n = 17), 
MLF (Ishak 1; n = 20), ALF (Ishak 2 + 3; n = 24), SLF (Ishak 4 + 5; n = 17), and LC (Ishak 6; n = 20).
Statistical analysis. All statistical analyses were performed with IBM SPSS Statistics (version 23, 
Chicago, IL, USA) and R 3.2.1. The data are presented as the mean ± the standard deviation (SD). We 
used the non-parametric Mann-Whitney U-test for independent variables and the Wilcoxon signed-rank 
test for dependent variables for comparisons between the groups. ROC analyses were performed to dif-
ferentiate between the patient groups, and the optimal cut-offs were estimated according to the Youden 
indices. The estimates of the AUCs that corresponded to the 95% confidence intervals and the true 
classification rates are reported. All tests were two-sided, and values of p < 0.05 indicated a significant 
difference.
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